Clinical Trial

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Study acronym: ATPase
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 20, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-14; most recent amendment 2024-09-17.
Status change: Completed → Recruiting 2024-05-29
Trial Details
NCT Number NCT05014464
Lead Sponsor Hunan Province Tumor Hospital
Conditions Non-small Cell Lung Cancer
Enrollment 90 participants
Start Date 2021-11-13
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-08-08 (estimated)
Updated on ClinicalTrials.gov 2024-09-20